Home/Filings/4/A/0001213900-25-059791
4/A//SEC Filing

Van Lent Eric R 4/A

Accession 0001213900-25-059791

CIK 0001690080other

Filed

Jun 29, 8:00 PM ET

Accepted

Jun 30, 5:31 PM ET

Size

8.4 KB

Accession

0001213900-25-059791

Insider Transaction Report

Form 4/AAmended
Period: 2025-06-17
Van Lent Eric R
Chief Accounting Officer
Transactions
  • Award

    Common Stock

    2025-06-17+8,1748,174 total
  • Award

    Non-Qualified Stock Option (right to buy)

    2025-06-17+25,00025,000 total
    Exercise: $0.93Exp: 2035-06-17Common Stock (25,000 underlying)
Footnotes (3)
  • [F1]Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/2 of such shares on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2022 Equity Compensation Plan (the "Equity Plan").
  • [F2]Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as Chief Accounting Officer of the Issuer.
  • [F3]The options vest 1/2 on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2025 Option Incentive Plan. The 2025 Option Incentive Plan is subject to stockholder approval and (i) no options can be exercised prior to obtaining stockholder approval for such plan, and (ii) the outstanding options will be cancelled, if stockholder approval is not obtained.

Documents

1 file

Issuer

180 Life Sciences Corp.

CIK 0001690080

Entity typeother

Related Parties

1
  • filerCIK 0002057653

Filing Metadata

Form type
4/A
Filed
Jun 29, 8:00 PM ET
Accepted
Jun 30, 5:31 PM ET
Size
8.4 KB